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Introduction
As to diabetes mellitus, the adequate management and treatment 
has been one of the important medical problems worldwide.1 The 
prevalence of diabetes has been gradually increasing every year.2 
For the diabetic treatment, diet therapy is the fundamental therapy, 
and various dietary therapies have been reported so far.3 There are 
variety kinds of diet, including low-carbohydrate diet (LCD), low-
fat diet (calorie restriction, CR), vegetarian diet, high protein diet, 
Mediterranean dietary pattern, Paleolithic diet, low-glycemic index/
load diet. 
Among them, recent topic has been the clinical application of 
LCD.4 There were lots of papers about comparison between LCD and 
CR.5 CR has been prevalent for standard diabetic nutritional therapy 
before. After that, Bernstein and colleagues initiated LCD some 
decade’s ago.6 Consecutively, the efficacy of LCD has been reported 
by the investigators of Dietary Intervention Randomized Controlled 
Trial (DIRECT) Group and others.7 Consequently, the nutrition 
method of LCD has been prevalent in North American and European 
countries.8 
In contrast, authors and colleagues have firstly reported LCD 
in medical practice in Japan.9 Furthermore, authors have continued 
various clinical researches concerning LCD for years. LCD has 
brought patients with gestational diabetes improved glucose 
variability and increased values of blood ketone bodies in fetuses, 
placenta, neonates, and mother, indicating the physiological role of 
ketone bodies.10 Moreover, we have reported the correlation between 
daily profile of blood glucose and M value.11 We have continued 
clinical research of LCD and given lectures about LCD through Japan 
LCD promotion association (JLCDPA).12 
On the other hand, clinical application of continuous glucose 
monitoring (CGM) has recently started, which is FreeStyle Libre 
(Abbott).13 It automatically measures blood glucose every 15minutes. 
From clinical experiences, it has been evaluated to be simple and 
useful that can be available in the medical practice.14 
Using CGM, we have studied glucose variability in diabetic 
patients.15 Among them, we have several clinically impressive cases. 
A case with type 1 diabetes mellitus (T1DM) was presented studied 
by CGM in this report. 
Case report
Present History: Subject enrolled was a female patient who was 
diagnosed as type 1 diabetes mellitus (T1DM) at the age of 44. She 
has continued to be treated with insulin for 10years. Currently, her 
diabetic control has been not so stable. HbA1c values for 1year have 
been about 7.5-8.8%. She is 54 years old treated with insulin therapy 
for 10years. The diabetic control was formerly stable, but it is rather 
unstable with HbA1c around 8% during half year. There are rather 
often hypoglycemic episodes when her daily life becomes rather 
unstable. Her blood glucose variety has ranged about from 50mg/dL 
to 380mg/dL.
Because of this unstable diabetic situation, it was advised that 
further evaluation of glucose variability would be necessary for better 
glucose control. Consequently, we have tried to investigate the detail 
profile of blood glucose using Free Style Libre.
Physical examination: Her consciousness is alert, and her 
physicals are unremarkable including pulse rate, blood pressure, body 
temperature and respiration rate. Her physicals were normal with 
lung, heart and abdomen. Neurologically, there are no remarkable 
findings. Her body mass index (BMI) was 21.4kg/m2.
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Abstract
Background: The problem of glucose variability has been in focus for type 1 diabetes 
mellitus (T1DM) on insulin treatment. Daily profile of blood glucose was studied on 
Continuous Glucose Monitoring (CGM) using Free Style Libre. 
Case presentation and results: Patient is 54 year-old T1DM female, with HbA1c 
7.8%. The blood glucose variability was measured by Free Style Libre. Insulin therapy 
included multiple daily insulin injection (MDI) of Insulin Glargin and Aspart. The 
result revealed unstable blood glucose profile in day 1 and 2. After that, the level and 
fluctuation of blood glucose gradually decreased from day 3 to 14. Average blood 
glucose in a day was 174mg/dL, 159mg/dL, 138mg/dL, 125mg/dL and 110mg/dL, in 
day 2, 4, 7, 9, 11, respectively. There was a discrepancy of HbA1c between 7.8% by 
laboratory measurement and 6.3% presumed value by Free Style Libre.
Discussion and Conclusion: Free Style Libre showed satisfactory results as CGM. 
There was lower HbA1c value by presumed calculation, which would be possibly due 
to every 15minutes measurement and difficulty in checking abrupt glucose surges. 
CGM application would probably bring diabetic subjects behavioral change of life 
style, leading to better diabetic control. These results would become reference data in 
CGM study for future research.
Keywords: Continuous Glucose Monitoring (CGM), Free Style Libre, type 1 diabetes 
mellitus (T1DM), mean absolute relative difference (MARD), low carbohydrate diet 
(LCD), Japan LCD promotion association (JLCDPA)
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Laboratory examination: Her results of laboratory examination on 
routine were in the following. The main data were: Hb 14.1 g/dL, WBC 
6000/μL, Plt 31.4 x 104/μL, AST 24U/mL, ALT 26U/mL, r-GT 23U/
mL, Alb 4.2mg/dL, BUN 17mg/dL, Cre 0.7mg/dL, Uric Acid 5.5mg/
dL, HDL 41mg/dL, LDL 103mg/dL, TG 146mg/dL. Laboratory data 
concerning diabetes include that HbA1c 8.2%, glucose 367mg/dL. 
Treatment with insulin: The patient has been treated with 2kinds of 
insulin for years. The insulin administration method has been multiple 
daily insulin injection (MDI). It includes Insulin Glargin (Eli Lilly 
and Company) at night once a day and Novo rapid (Novo Nordisk) 
three times a day. The former is Insulin Glargin by BS injection kit 
FFP including 300units/mL and the latter is Insulin Aspart provided 
by pre–filled pen including 100units/mL. The schedule of the insulin 
therapy a day was that Glargin is given 13units on 2300h and Aspart 
is given 23, 23, 23units on 0800h, 1200h, 1700h.
Blood variability by CGM: The patient had the study of CGM 
by Free Style Libre (Abbott, USA) in January 2019. The profile of 
blood glucose for continuous 14days was investigated. During two 
weeks, there were no specific symptoms, signs or problems related 
to diabetes. 
 The glucose variability for day 2 to day 11 is revealed in Figure 1. 
The average glucose level a day was decreased from day 1 to day 14. 
Average blood glucose in a day was 174mg/dL, 159mg/dL, 138mg/
dL, 125mg/dL and 110mg/dL, in day 2, 4, 7, 9, 11, respectively. In day 
2 and 4there were rather larger fluctuation of daily glucose profile. In 
day 9, 11, however, there was little fluctuation of daily glucose.
Figure 1 Blood Glucose variability by Free Style Libre from day 2 to day 11.
According to the results of Figure 1, the relationship between blood 
glucose value at any moment and symptom/sign can be studied. She 
felt a little thirsty at 2130h on day 2 with blood glucose 380mg/dL, 
and moderate hungry at 1600h on day 11 with blood glucose 70mg/
dL. These episodes are beneficial for investigating the correlation 
between hyperglycemia / hypoglycemia and present symptom / sign 
in each patient. 
Furthermore, Figure 1 showed the estimated HbA1c value which 
was 6.3% or 45mmol/mol. At that time, her HbA1c value was 7.8% on 
day 1. Thus, some discrepancy was found between the actual HbA1c 
value in the out clinic and that calculated by the FreeStyle Libre. 
Continuous Glucose Monitoring (CGM)
Recently, Continuous Glucose Monitoring (CGM) system has 
been introduced in the medical practice as a sensor-based device for 
blood glucose monitoring.16 It is the Free Style Libre, which was 
produced by Abbott, USA.16 From its continuous research and clinical 
trials for long years, it has been estimated to be simple and useful for 
detecting blood glucose variability. It is also beneficial for convenient 
and precise, as well as small size for actual clinical practice.17
Discussion
This report presented 54 year-old female with T1DM on multiple 
daily insulin injection (MDI). Her problem has been unstable blood 
glucose variability for several months. It included several factors, 
such as irregular lifestyle, persisting general malaise physiologically 
and various stressful situation psychologically.18 
Using the useful Free Style Libre, blood variability in daily profile 
was studied for 14days. According to the data of CGM, blood glucose 
had gradually decreased. Not only the average glucose but also the 
fluctuation of the blood glucose were also decreased gradually. 
There are some reasons why she could bring her blood glucose 
controlled in 10days. The possibilities were that i) her daily life became 
rather stable in diet, work and exercise, ii) psychological stressors 
were moderately reduced as to inter-personal communication, iii) 
the amount of carbohydrate such as bread, rice and noodles was a 
little decreased, iv) she can always grasp the current blood glucose 
variability for 24hours, just manipulating her Smartphone and v) 
changing levels of glucose can control her behaviors.19 
As mentioned above, moving data of blood glucose calculated by 
CGM have definitely good opportunity to make the diabetic patient 
change the lifestyle. In other words, CGM can cause behavioral 
change for the patient, which would be greatly beneficial medically, 
physically and psychologically.
 According to the description of CGM recommendations in the 
guideline-2019, it is to improve glycemic control without an increase 
in hypoglycemia or severe hypoglycemia.20 Its benefits will correlate 
with adherence to ongoing use of the device, which has the level of 
evidence as rank A. 
From the basic aspect of Free Style Libre, Updike et al. introduced 
the enzyme electrode method long ago.21 Consecutively, the electrodes 
were developed and various experiments were tried for CGM.22 The 
guideline of CGM has been shown and many research have continued 
about concerning international standardization, which are mean 
absolute relative deviation (MARD) and precision absolute relative 
difference (PARD).23,24 
From clinical aspect of Free Style Libre, the beneficial point would 
be the easy measurement of blood glucose variability. On the other 
hand, there was the discrepancy between HbA1c value from the 
laboratory company and the estimated HbA1c value calculated by 
Free Style Libre from obtained blood glucose data. This phenomenon 
would be partly due to the fact that CGM would not detect occasional 
abrupt changes or spike-like elevation of blood glucose.25 There would 
be another reason that blood glucose is measured in every 15minutes 
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for Free Style Libre. Consequently, further evaluation with various 
data accumulation would be necessary in the future.
In summary, blood glucose variability was monitored by Free 
Style Libre in a female patient with T1DM. Average and fluctuation 
of blood glucose were decreased during 2weeks. It is supposed that 
CGM application would bring the subject behavioral changes, leading 
to better diabetic control. These results are expected to be reference 
data in CGM study for future research.
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